Sign in Sign up for free

Last updated: 12 June 2024 at 5:55pm EST

Jami Rubin Net Worth




The estimated Net Worth of Jami Rubin is at least $522 Thousand dollars as of 10 June 2024. Jami Rubin owns over 42,242 units of Relay Therapeutics stock worth over $521,798 and over the last 4 years Jami sold RLAY stock worth over $0.

Jami Rubin RLAY stock SEC Form 4 insiders trading

Jami has made over 2 trades of the Relay Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Jami exercised 42,242 units of RLAY stock worth $212,900 on 10 June 2024.

The largest trade Jami's ever made was exercising 42,242 units of Relay Therapeutics stock on 10 June 2024 worth over $212,900. On average, Jami trades about 11,207 units every 237 days since 2020. As of 10 June 2024 Jami still owns at least 67,242 units of Relay Therapeutics stock.

You can see the complete history of Jami Rubin stock trades at the bottom of the page.



What's Jami Rubin's mailing address?

Jami's mailing address filed with the SEC is C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, 2ND FLOOR, CAMBRIDGE, MA, 02139.

Insiders trading at Relay Therapeutics

Over the last 4 years, insiders at Relay Therapeutics have traded over $234,228,237 worth of Relay Therapeutics stock and bought 110,000 units worth $2,200,000 . The most active insiders traders include Rock Ventures Iii, L.P.Thir..., Sanjiv Patel, and Donald A Bergstrom. On average, Relay Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $406,570. The most recent stock trade was executed by Thomas Catinazzo on 29 July 2024, trading 10,780 units of RLAY stock currently worth $92,277.



What does Relay Therapeutics do?

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.



What does Relay Therapeutics's logo look like?

Relay Therapeutics, Inc. logo

Complete history of Jami Rubin stock trades at Relay Therapeutics

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
10 Jun 2024 RLAY Relay Therapeutics, Inc. Jami Rubin
Option 42,242 $5.04 $212,900
10 Jun 2024
67,242 ↗
20 Jul 2020 RLAY Relay Therapeutics, Inc. Jami Rubin
Buy 25,000 $20.00 $500,000
20 Jul 2020
25,000 ↗


Relay Therapeutics executives and stock owners

Relay Therapeutics executives and other stock owners filed with the SEC include: